Insight Molecular Diagnostics (IMDX) Operating Expenses (2015 - 2026)

Insight Molecular Diagnostics has disclosed Operating Expenses across 12 years of filings, most recently posting $4.4 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $4.4 million, down 45.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.7 million (down 17.91% YoY), and the FY2025 annual result was $53.4 million, down 13.53% from the prior year.
• Operating Expenses came in at $4.4 million for Q1 2026 at Insight Molecular Diagnostics, down from $23.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $34.2 million in Q4 2024 to a low of -$5.8 million in Q1 2023.
• The 5-year median for Operating Expenses is $8.6 million (2023), against an average of $9.6 million.
• Peak annual rise in Operating Expenses reached 416.96% in 2023, while the deepest fall reached 278.92% in 2023.
• Insight Molecular Diagnostics' Operating Expenses stood at $11.6 million in 2022, then surged by 38.22% to $16.1 million in 2023, then soared by 113.06% to $34.2 million in 2024, then plunged by 30.07% to $23.9 million in 2025, then tumbled by 81.5% to $4.4 million in 2026.
• The last three Operating Expenses figures came in at $4.4 million (Q1 2026), $23.9 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.